InMed Pharmaceuticals (INM) Gross Profit (2021 - 2025)

InMed Pharmaceuticals has reported Gross Profit for 5 years, with the latest figure at $184194.0 in Q4 2025.

• On a quarterly basis, Gross Profit fell 60.04% year-over-year to $184194.0 in Q4 2025; TTM through Dec 2025 was $1.3 million, a 21.65% decrease from a year earlier, with the FY2025 full-year figure at $1.7 million, up 55.02% from the prior year.
• Gross Profit was $184194.0 for Q4 2025 at InMed Pharmaceuticals, down from $403159.0 in the prior quarter.
• The five-year high for Gross Profit was $1.6 million in Q2 2023, with the low at -$491018.0 in Q3 2022.
• Average Gross Profit over 5 years is $314202.0, with a median of $249714.0 recorded in 2022.
• The largest YoY upside for Gross Profit was 2222.82% in 2024 against a maximum downside of 70.32% in 2024.
• Over 5 years, Gross Profit stood at $111555.0 in 2021, then rose by 17.58% to $131163.0 in 2022, then soared by 147.13% to $324142.0 in 2023, then jumped by 42.19% to $460894.0 in 2024, then sank by 60.04% to $184194.0 in 2025.
• The last three Gross Profit figures came in at $184194.0 (Q4 2025), $403159.0 (Q3 2025), and $576654.0 (Q2 2025), per Business Quant data.